Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Taking into account that 5 out of 22 patients in the Reparixin group experienced EAD during the first stage of the study, according to the Protocol and the DMC conclusion, it was decided on the early termination of the study

Conditions

Ischemia-reperfusion Injury in Liver Transplant
Early Allograft Dysfunction

Interventions

DRUG: Reparixin
OTHER: Control

Sponsor

Dompé Farmaceutici S.p.A